Zebinix Shows Long-Term Reduction In Seizure Frequency

Results from the one-year extension of a pivotal Eslicarbazepine Acetate phase III study showed that add-on treatment with once-daily anti-epileptic Zebinix (eslicarbazepine acetate; ESL), resulted in a sustained decrease in seizure frequency over the long-term.

Data showed that patients, not controlled with existing anti-epileptic drugs who were given eslicarbazepine acetate as an add-on treatment, experienced a mean reduction in seizure frequency of more than 61%.

Pooled data from more than 1,000 patients enrolled in the three pivotal phase-III studies demonstrated, that add-on therapy with once-daily Zebinix (800mg and 1200mg) was effective in reducing partial-onset seizures in patients not controlled with one of the most commonly used anti-epileptics, carbamazepine (CBZ).

Joyce Cramer, Research Scientist at Yale University School of Medicine and President of The Epilepsy Therapy Project, said: These data continue to demonstrate the efficacy and safety of Zebinix in the treatment of partial onset seizures. The availability of eslicarbazepine acetate adds an important new choice of therapy for patients who are in vital need of better seizure control.